Scher RK, Coppa LM: Advances in the diagnosis and treatment of onychomycosis. Hosp Med 34: 11, 1998.
Ghannoum MA, Hajjeh RA, Scher R, et al: A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. J Am Acad Dermatol 43: 641, 2000.
Mozena J: A guide to treatments for onychomycosis. Podiatry Today 2003; 16(8).
Baran R, Sigurgeirsson B, de Berker D, et al: A multicentre, randomized, controlled study of the efficacy, safety and cost-effectiveness of a combination therapy with amorolfine nail lacquer and oral terbinafine compared with oral terbinafine alone for the treatment of onychomycosis with matrix involvement. Br J Dermatol 157: 149, 2007.
Prescrire R: Fungal nail infections: diagnosis and management. Prescrire Int 18: 26, 2009.
de Berker D: Fungal nail disease. N Engl J Med 360: 2108, 2009.
Ghannoum MA, Long L, Pfister WR: Determination of the efficacy of terbinafine hydrochloride nail solution in the topical treatment of dermatophytosis in a guinea pig model. Mycoses 52: 35, 2009.
Elewski BE, Ghannou MA, Mayser P, et al: Efficacy, safety and tolerability of topical terbinafine nail solution in patients with mild-to-moderate toenail onychomycosis: results from three randomized studies using double-blind vehicle-controlled and open-label active-controlled designs. J Eur Acad Dermatol Venereol 27: 287, 2013.
Elewski BE, Rich P, Pollak R, et al: Efinaconazole 10% solution in the treatment of toenail onychomycosis: two phase 3 multicenter, randomized, double-blind studies. J Am Acad Dermatol 68: 600, 2013.
De Cuyper C, Hindryckx PH: Long-term outcomes in the treatment of toenail onychomycosis. Br J Dermatol 141(Suppl 56): 15, 1999.
Werschler WP, Bondar G, Armstrong D: Assessing treatment outcomes in toenail onychomycosis clinical trials. Am J Clin Dermatol 5: 145, 2004.
Piraccini BM, Sisti A, Tosti A: Long-term follow-up of toenail onychomycosis caused by dermatophytes after successful treatment with systemic antifungal agents. J Am Acad Dermatol 62: 411, 2010.
Gupta AK, Schouton, JR, Jynch LE: Ciclopirox nail lacquer 8% for the treatment of onychomycosis: a Canadian perspective. Skin Therapy Lett 10: 1, 2005.
Gupta AK, Joseph WS: Ciclopirox 8% nail lacquer in the treatment of onychomycosis of the toenails in the United States. JAPMA 90: 495, 2000.
Onychomycosis is a very common disease, especially in podiatric medical practice. It can be associated with significant patient distress, major disability and pain, and is challenging to treat successfully. This is a case study of a 41-year-old man with distal lateral subungual onychomycosis of 5 years' duration. Forty percent of the great toenail was affected and a total of six toenails were involved. Baseline fungal cultures were positive for Trichophyton rubrum. This patient was treated with efinaconazole 10% solution, a new topical antifungal, once daily for 48 weeks. Mycological cure was noted at the first assessment period (12 weeks), and compete cure was seen at follow-up. This case study alerts physicians to a promising new topical treatment for onychomycosis under development, and to the importance of mycological cure as an early indicator of treatment success.